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BACKGROUND The long-term safety and efﬁcacy of stent overlap
with second-generation drug-eluting stents (DES) have not been well
established. We evaluated long-term clinical outcomes of overlapping
everolimus-eluting stent (EES), as compared with sirolimus-eluting
stent (SES).
METHODS This study was conducted on a multicenter database of
percutaneous coronary intervention with DES. 903 Patients (SES,
n¼537; EES, n¼366) were enrolled based on the following inclusion
criteria: (1) patient receiving two overlapping SES or EES, and (2)
follow-up period of at least four years. We evaluated major adverse
cardiovascular event (MACE), deﬁned as the composite of all-cause
death, non-fatal myocardial infarction (MI) or target lesion revascu-
larization (TLR).
RESULTS During the four years, follow-up EES showed a lower rate of
MACE and TLR rate, as compared to SES (13% vs. 19%, p¼0.027; 3% vs.
7% p¼0.014, respectively). All-cause deaths and non-fatal MI rates
were not signiﬁcantly different between the EES and SES groups (9%
vs. 9%, p¼0.734; 2% vs. 3%, p¼0.259, respectively). After propensity-
score matching, the MACE and TLR of rate of EES group were signif-
icantly lower than those of SES group.
CONCLUSIONS Overlapping EES showed a signiﬁcant lower rate in
MACE and TLR, as compared to SES, in the long-term clinical follow-
up.
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BACKGROUND Aspirin forms a crucial backbone of the Antiplatelet
pharmacotherapy in patients undergoing percutaneous coronaryintervention (PCI). However, there is uncertainty regarding the
optimal dose to be prescribed. We aim to perform a systematic liter-
ature review on all studies comparing treatment with low and high
dose aspirin in patients undergoing PCI.
METHODS A comprehensive literature search was performed by 2
independent reviewers utilizing MEDLINE, EMBASE and Cochrane
Library databases. All trials comparing low dose and high dose aspirin
in patients undergoing PCI were selected. Low dose was deﬁned
as <162mg and high dose as 162mg. Outcomes measured included
major adverse cardiovascular events (MACE), deﬁned as the
composite of death, reinfarction, stroke and target vessel revascular-
ization, and bleeding. In combining evidence across the trials, a ﬁxed-
effect method in RevMan 5.3 was used after ruling out heterogeneity
based on the I2 test (I2<40%) to obtain hazards ratios for the
outcomes.
RESULTS Five studies with a total of 27,456 patients were selected.
Two studies evaluated outcomes at 30 days and three studies at 1
year. No signiﬁcant difference was found in MACE rates when eval-
uating low dose against high dose aspirin (HR [95% CI], 1.03 [0.93-
1.15]; p¼0.55). Bleeding rates were signiﬁcantly lower in the low dose
aspirin group as compared to the high dose group (HR [95% CI], 0.64
[0.50-0.83]; p¼0.0005). Two studies reporting stent thrombosis rates
did not show any difference between both groups.
CONCLUSIONS Although there was no signiﬁcant difference in MACE
rates between the high and low dose aspirin groups, the high dose
aspirin group appeared to be at a signiﬁcantly increased risk of
bleeding complications. This lends weight to the use of low dose
aspirin in patients undergoing PCI.
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BACKGROUND Whether a smoker’s paradox exists with regards to
early and late mortality outcomes for patients undergoing percuta-
neous coronary intervention (PCI) for acute coronary syndrome (ACS)
is debated. Studies have produced inconclusive data on whether such
a paradox exists or whether it can be explained by confounding
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double paradox exist in this patient cohort is not clear.
METHODS 5924 patients who underwent PCIs for ACS in two hospitals
were analyzed. Statistical analyses were performed to analyze the
respective relationship between smoking status and obesity (BMI >¼
30 kg/m2) and both in-patient and late mortality outcomes following
PCI. In addition, we used an interaction model to analyze the inter-
action between smoking and obesity on subsequent mortality
outcomes.
RESULTS Of the 5924 PCIs, 1086 were performed on patients who
were smokers. In unadjusted analyses, adverse late mortality out-
comes (mean 2.5 years follow-up) in smokers were signiﬁcantly lower
compared to non-smokers (p<0.01). After propensity score-adjust-
ment, late mortality was not signiﬁcantly different between the two
groups (HR 0.63, 95% CI 0.40-1.01, p¼0.06). Of the 5924 PCIs, 2076
were performed on patients who were obese. In unadjusted analyses,
adverse late mortality outcomes (mean 2.5 years follow-up) in obese
patients were signiﬁcantly lower than they were in non-obese patients
(p<0.01). After propensity score-adjustment, obese patients’ late
mortality outcomes were not signiﬁcantly different than patients with
BMI < 30 (HR 0.98, 95% CI 0.70 – 1.37). Furthermore, we found no
signiﬁcant interaction between smoking status and BMI on late mor-
tality (p¼0.82).
CONCLUSIONS We did not ﬁnd evidence of a smoker’s paradox,
obesity paradox or an obese-smoker double paradox for early and late
mortality outcomes post-PCI. Existence of such paradox in the prior
literature might be explained by confounding factors.
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BACKGROUND Recent studies have demonstrated that optimal
coherence tomography (OCT) guided percutaneous coronary inter-
vention (PCI) was useful to prevent major adverse cardiac events after
PCI. However, optimal Drug-eluting stent (DES) expansion using OCT
has not been established yet. The aim of this study to assess optimal
DES expansion at post stenting to prevent target lesion revasculari-
zation (TLR) at 8-month follow-up.METHODS Until May 2015, we performed OCT guided DES implanta-
tion and 8 months follow-up coronary angiography in 91 patients.
There were 14 TLRs (15.4%) including 6 in-stent and 8 stent edge
restenosis (4 proximal, 4 distal). After excluding 1 stent edge reste-
nosis due to stent edge injury, 13 TLRs were analyzed in this study
(TLR, N¼13; non-TLR, N¼77). Lipid rich plaque (deﬁned by lipid
occupying S2 quadrants of the cross-section area), thin cap ﬁbroa-
theroma (TCFA ,deﬁned as lipid-rich plaque with ﬁbrous cap thickness
&65mm) , plaque calciﬁcation, and thrombus (deﬁned as an irregular
mass protruding into the lumen with dimension S200 mm) were
measured at pre PCI. Minimal stent area (MSA), % stent expansion,
stent symmetry, and tissue protrusion were measured at post PCI.
RESULTS There were no signiﬁcant differences in clinical character-
istics between groups, except age (TLR was younger than non-TLR;
6411 vs 719, P¼0.02). TCFA and lipid rich plaque were lower in TLR
than in non-TLR (7.7% vs 23%, P¼0.12; 30% vs 45%, P¼0.18). There
were no signiﬁcant differences in plaque calciﬁcation, thrombus, %
stent expansion, stent symmetry, and existence of tissue protrusion
between TLR and non-TLR (46% vs 54%; 0.33%, 15% vs 14%; 0.42%,
85.1%27.3% vs 96.5%28.5%, P¼0.13;0.850.08 vs 0.850.08,
P¼0.86; 30% vs 22%, P¼0.50). MSA was signiﬁcantly smaller in TLR
than in non-TLR (4.31.9 vs 5.71.6, P<0.01). On multivariable anal-
ysis, Age and MSA were independent predictors of TLR (OR 1.11, 95%
CI 1.02-1.24, P¼0.02; OR¼2.58: 95%CI 1.14-7.68, P¼0.04). The best cut-
off value to prevent TLR was 4.7mm2 (sensitivity 74%, speciﬁcity 77%,
positive predict value 95%, negative predict value 33.3%).
CONCLUSIONS OCT guided DES expansion during PCI may be useful
to prevent TLR. The optimal MSA at post procedure to prevent TLR
was 4.7mm2.
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BACKGROUND Indication of side branch (SB) intervention after main
vessel (MV) stenting is not established in coronary bifurcation lesions.
This study sought to investigate differential effect of SB intervention
on long-term clinical outcomes according to SB stenosis after MV
stenting.
METHODS In the Coronary Bifurcation Stenting II Registry, 2,897 pa-
tients undergoing percutaneous coronary intervention using drug-
eluting stents for bifurcation lesions with SB 2.3 mm were enrolled.
We selected 2,017 patients treated with 1-stent technique or MV
stenting ﬁrst strategy. Patients undergoing SB intervention after MV
stenting (SB intervention group, n¼929) were compared to those not
after MV stenting (no-SB intervention group, n¼1,088) in terms of
cardiac death or myocardial infarction (MI).
RESULTS During a median follow-up duration of 37 months, the cu-
mulative rate of cardiac death or MI tended to occur less frequently in
the SB intervention group than in the no-SB intervention group (1.8 %
versus 2.9%; adjusted HR 0.56; 95% CI 0.29 to 1.07; p¼0.08). There
was signiﬁcant interaction between SB intervention and SB stenosis
after MV stenting. Of 1,077 patients with diameter stenosis of SB 50%
after MV stenting, SB intervention was associated with a lower risk of
cardiac death or MI (1.2% versus 4.2%; adjusted HR 0.22; 95% CI 0.09
to 0.52; p¼0.001). However, among 940 patients with diameter ste-
nosis of SB <50%, there was no signiﬁcant difference in cardiac death
or MI (3.5% versus 2.2%; adjusted HR 1.36; 95% CI 0.58 to 3.20;
p¼0.48) between the SB intervention group and the no-SB interven-
tion group. Rate of target lesion revascularization was not signiﬁ-
cantly different between the 2 groups regardless of SB stenosis.
CONCLUSIONS Effect of SB intervention differs according to SB ste-
nosis after MV stenting. SB intervention may reduce cardiac death or
MI in bifurcation lesions with diameter stenosis of SB 50% after MV
stenting.
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